NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

28 Apr 2025 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

25 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

17 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2025 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

08 Apr 2025 16:00:00 By Nasdaq GlobeNewswire

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

02 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

25 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

17 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Mar 2025 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

13 Mar 2025 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

04 Mar 2025 07:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Feb 2025 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

28 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

22 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

09 Dec 2024 18:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire